| [1] | Dickersin K (1990) The existence of publication bias and risk factors for its occurrence. JAMA 263: 1385–1389.
|
| [2] | Chan AW, Hróbjartsson A, Haahr MT, G？tzsche PC, Altman DG (2004) Empirical evidence for selective reporting of outcomes in randomized trials: Comparison of protocols to published articles. JAMA 291: 2457–2465.
|
| [3] | Bekelman JE, Li Y, Gross CP (2003) Scope and impact of financial conflicts of interest in biomedical research. JAMA 289: 454–465.
|
| [4] | The PLoS Medicine Editors (2008) Making sense of non-financial competing interests. PLoS Med 5: e199. doi:10.1371/journal.pmed.0050199.
|
| [5] | Davidoff F, DeAngelis CD, Drazen JM, Nicholls MG, Hoey J, et al. (2001) Sponsorship, authorship, and accountability. N Engl J Med 345: 825–826.
|
| [6] | Pool R (2000) Material transfer agreements.
|
| [7] | Dickersin K (2008) Reporting and other biases in studies of Neurontin for migraine, psychiatric/bipolar disorders, nociceptive pain, and neuropathic pain. Available: http://dida.library.ucsf.edu/tid/oxx18r1？0. Accessed 22 January 2009.
|
| [8] | Landefeld CS, Steinman MA (2009) The Neurontin legacy: Marketing through misinformation and manipulation. New Engl J Med 360: 103–106.
|
| [9] | Armstrong D (2006 May 15) How the New England Journal missed warning signs on Vioxx. The Wall Street Journal. Available: http://online.wsj.com/article/SB11476543？0315252591.html. Accessed 22 January 2009.
|
| [10] | Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520–1528.
|
| [11] | Smith R (2005) Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2: e138. doi:10.1371/journal.pmed.0020138.
|
| [12] | PLoS Medicine (2009) Open-access license. Available: http://journals.plos.org/plosmedicine/li？cense.php. Accessed 22 January 2009.
|
| [13] | PLoS Medicine (2009) Competing interests of the PLoS Medicine Editors. Available: http://journals.plos.org/plosmedicine/ed？itors_interests.php. Accessed 22 January 2009.
|
| [14] | Zimmers TA, Sheldon J, Lubarsky DA, López-Mu？oz F, Waterman L, et al. (2007) Lethal injection for execution: Chemical asphyxiation. PLoS Med 4: e156. doi:10.1371/journal.pmed.0040156.
|
| [15] | The PLoS Medicine Editors (2007) Lethal injection is not humane. PLoS Med 4: e171. doi:10.1371/journal.pmed.0040171.
|
| [16] | G？tzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, et al. (2009) What should be done to tackle ghostwriting in the medical literature. PLoS Med 6: e1000023. doi:10.1371/journal.pmed.1000023.
|
| [17] | Flanagin A, Carey LA, Fontanarosa PB, Phillips SG, Pace BP, et al. (1998) Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 280: 222–224.
|
| [18] | Chan AW (2008) Bias, spin, and misreporting: Time for full access to trial protocols and results. PLoS Med 5: e230. doi:10.1371/journal.pmed.0050230.
|
| [19] | Consolidated Standards of Reporting Trials (2009) The CONSORT statement. Available: http://www.consort-statement.org/. Accessed 22 January 2009.
|
| [20] | World Medical Association (2008) Declaration of Helsinki. Available: http://www.wma.net/e/policy/b3.htm. Accessed 22 January 2009.
|
